EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

FROM FIASP TO TRURAPI: CONVERSION IN INSULIN ASPART PRESCRIBING IN THE UNITED KINGDOM AND THE IMPACT OF DELIVERY-DEVICE PREFERENCES

Heba M. Attash

Global Journal of Public Health Medicine · 18.08.2026 · 8 (1 (Ongoing)) · 200-215

DOI: 10.37557/87533971 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Global Journal of Public Health Medicine, online erschienen am 18.08.2026. Verfasst von Heba M. Attash. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

In England, NovoRapid® dominated the rapid-acting insulin aspart market until 2017, when Fiasp® (next-generation fast-acting aspart) was launched, followed by Trurapi® (similar to NovoRapid®) after UK approval in 2021 (European marketing authorization 2020).

Methods

Prescribing information from NHS primary care data was aggregated and adjusted to defined daily doses (DDD, 40 IU) between 2008 and 2024. Segmented regression models with two intervention points (Fiasp® Q1 2017, Trurapi® Q4 2021) were estimated, with separate analyses by device (pre-filled pens, cartridges, vials).

Results

NovoRapid® continued to increase until 2017, when the growth slowed after the introduction of Fiasp. Fiasp® grew rapidly after launch and was approximately 1.25 million DDDs (95% CI 0.42 to 2.08 million) above the counterfactual two years after Trurapi® was introduced (p < 0.001). The uptake of Trurapi® was typical of biosimilar products, with approximately 5.4% of the market share by Q4 2024 (95% CI 4.8% to 7.2%). Adoption was greater in pens and cartridges than in vials, reflecting prescribers’ and patients’ familiarity with the originator products' pen platforms.

Conclusions

In 17 years, the England insulin aspart market was transformed with successive product launches. In addition to clinical comparability, familiarity with the device and the timing in the market lifecycle were key factors in adoption. Monitoring utilization at both brand and device level may help policymakers and prescribers with biosimilar integration and ensure patient confidence.

Zitieren

APA

Attash, H. M. (2026). FROM FIASP TO TRURAPI: CONVERSION IN INSULIN ASPART PRESCRIBING IN THE UNITED KINGDOM AND THE IMPACT OF DELIVERY-DEVICE PREFERENCES. Global Journal of Public Health Medicine, 8(1 (Ongoing)), 200-215. https://doi.org/10.37557/87533971

Vancouver

Attash HM. FROM FIASP TO TRURAPI: CONVERSION IN INSULIN ASPART PRESCRIBING IN THE UNITED KINGDOM AND THE IMPACT OF DELIVERY-DEVICE PREFERENCES. Global Journal of Public Health Medicine. 2026;8(1 (Ongoing)):200-215. doi:10.37557/87533971

BibTeX
@article{Attash2026,
  author = {Attash, Heba M.},
  title = {FROM FIASP TO TRURAPI: CONVERSION IN INSULIN ASPART PRESCRIBING IN THE UNITED KINGDOM AND THE IMPACT OF DELIVERY-DEVICE PREFERENCES},
  journal = {Global Journal of Public Health Medicine},
  year = {2026},
  volume = {8},
  number = {1 (Ongoing)},
  pages = {200--215},
  doi = {10.37557/87533971}
}
Kostenlos starten →